Head-to-head · Cost-Efficiency Index
Invigor Medical vs Thryve
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalThryve
Not currently recommendable — include only for completeness while the underlying site remains this undocumented.
Visit ThryveThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 22. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. Thryve still earns a C — Not currently recommendable — include only for completeness while the underlying site remains this undocumented.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | Thryve |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 22/100 |
| Semaglutide / mo | $225/mo (starting dose) | $99/mo (drug not specified — site never names semaglutide or tirzepatide) |
| Tirzepatide / mo | $350/mo (starting dose) | $99/mo (drug not specified — site never names semaglutide or tirzepatide) |
| Semaglutide / yr (modeled) | $2,700 | $1,188 |
| Tirzepatide / yr (modeled) | $4,200 | $1,188 |
| Coverage | All 50 states | Not disclosed |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #8 | #501 |
Invigor Medical
88/100Where the value is
- Competitive mid-market 'starting at' pricing on both semaglutide and tirzepatide
- Licensed in all 50 states, with a named Medical Director (Dr. Hamilton) and five named partner compounding pharmacies
- Both molecules published up front for easy cost modeling
The tradeoffs
- Both prices are floors — no dose-tier breakdown is published, so the real cost at a typical maintenance dose is unknown until intake
- The site names five partner pharmacies but never discloses which one fills a given order
Thryve
22/100Where the value is
- A low headline price is advertised, if a reader wants to investigate directly
The tradeoffs
- Never names which drug is being sold — no mention of semaglutide, tirzepatide, or any other active ingredient anywhere on the site
- No dose, no state-coverage list, no named clinician, and no named pharmacy found anywhere
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.